UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 605,928 Shares of Amgen Inc. $AMGN

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 12.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 5,390,910 shares of the medical research company’s stock after buying an additional 605,928 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Amgen were worth $1,952,156,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Adell Harriman & Carpenter Inc. lifted its holdings in shares of Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after purchasing an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Amgen in the 4th quarter worth about $22,441,000. National Pension Service increased its holdings in Amgen by 4.7% in the 4th quarter. National Pension Service now owns 1,239,549 shares of the medical research company’s stock worth $405,717,000 after buying an additional 55,489 shares in the last quarter. Integrated Advisors Network LLC raised its position in Amgen by 50.5% in the 1st quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock worth $6,664,000 after buying an additional 6,356 shares during the last quarter. Finally, Legal & General Group Plc raised its position in Amgen by 2.5% in the 4th quarter. Legal & General Group Plc now owns 3,811,451 shares of the medical research company’s stock worth $1,247,526,000 after buying an additional 94,494 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last three months. 0.85% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on AMGN shares. Barclays raised their price target on shares of Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. Truist Financial boosted their price objective on shares of Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Bank of America increased their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 6th. Finally, Cantor Fitzgerald lifted their target price on shares of Amgen from $350.00 to $400.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $380.43.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire expands its potential market. Amgen and AstraZeneca reported that Tezspire met both co-primary and all key secondary endpoints in the Phase 3 CROSSING study for eosinophilic esophagitis (EoE). Improvements in tissue inflammation and swallowing symptoms were statistically significant, clinically meaningful and sustained through 52 weeks. EoE could become Tezspire’s third approved indication, adding a potentially significant growth opportunity beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 EoE Results
• Positive Sentiment: Recent financial performance remains supportive. Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Strong results and full-year guidance have helped keep the stock near its 52-week high and provide a favorable backdrop for pipeline news. Amgen Earnings and Guidance
• Neutral Sentiment: Additional pipeline updates offer limited near-term valuation impact. Amgen provided updates on a pediatric psoriasis study involving apremilast and began a Phase 1 trial of AMG 691 aimed at markets in Asia. These programs may support long-term growth, but both remain too early to materially affect current earnings expectations. Amgen Pediatric Psoriasis Study
• Negative Sentiment: Amgen ended its Crohn’s disease research partnership with TScan Therapeutics. Terminating the collaboration removes an external source of potential inflammatory bowel disease assets and may raise questions about the company’s strategy in this research area. The impact is likely limited near term because the program was still focused on target discovery. Amgen Ends Crohn’s Research Partnership

Amgen Stock Down 1.0%

Shares of AMGN stock opened at $432.42 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $447.03. The stock has a market cap of $233.78 billion, a P/E ratio of 26.88, a P/E/G ratio of 3.12 and a beta of 0.41. The company has a 50 day simple moving average of $388.64 and a two-hundred day simple moving average of $364.71.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter last year, the company posted $6.02 EPS. The company’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts expect that Amgen Inc. will post 22.97 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s payout ratio is 62.65%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.